Accelerating Science-Driven Reimbursement For Digital Therapeutics In State Medicaid Programs | Health Affairs Blog

Digital therapeutics have particular potential value for Medicaid patients. Yet the very technologies that may be able to help Medicaid beneficiaries achieve better health in times of COVID-19 and beyond cannot reach those patients because Medicaid benefit coverage processes in most states are nebulous and driven more by consultant relationships than by evidence.

Read the full article here

Related Articles